Citigroup Rates Glaukos (GKOS) buy, $162 Price Target
Citigroup has reiterated its buy rating on Glaukos Corporation, setting a price target of $162, a 24.48% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Citigroup rated Glaukos Corporation ($GKOS) "buy" with a $162 price target on June 11, 2026.
Since the rating, $GKOS is up 5.2% after 1 week, up 22.9% after 1 month and up 32.7% to date (from the $124.26 close on Jun 11, 2026).
GKOS
Glaukos Corporation
Key Points
- On June 11, 2026, Citigroup reiterated its buy rating on Glaukos Corporation (NYSE: GKOS) with a price target of $162, while the stock is currently priced at $130.14.
- Glaukos has seen strong revenue growth of 49.5% over the last year, yet it reported a net loss with an EPS of -3.28.
- The consensus among 12 analysts gives Glaukos a mean price target of $197.75, suggesting a potential upside from its current trading level.
Get $GKOS trade alerts by text
We text you when insiders, Congress or big funds trade $GKOS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Glaukos Corporation alert may contain errors. Disclosures
Citigroup Reiterates Positive Outlook
On June 11, 2026, Citigroup reiterated its buy rating on Glaukos Corporation (NYSE: GKOS) with a price target of $162. Currently, the stock is trading at $130.14, providing investors with a significant gap to the target price.
Analysts Set New Price Targets
The reiteration from Citigroup aligns with a generally positive outlook from analysts. Glaukos has a consensus mean price target of $197.75 based on 12 analyst opinions. This suggests there's room for growth as the stock trades below the average target, highlighting potential investor interest.
Stock Performance and Trading Context
As of today, Glaukos stock is at $130.14, significantly lower than its 52-week high of $191.62. The stock's position reflects a broader trend in the healthcare sector, where companies often face volatility based on market conditions and regulatory changes. The gap between the current price and Citigroup's target indicates a bullish outlook despite recent challenges.
$GKOS price target
Glaukos Corporation daily closes and this analyst's $162 target. Not advice.
Recent Earnings
Glaukos reported revenue of approximately $612.8 million, marking a 49.5% increase compared to the previous year. However, it continues to operate at a loss with an EPS of -3.28 and a net margin of -30.7%. The next earnings report is scheduled for October 28, 2026, which may provide additional insights into the company's financial health and future direction.
What Glaukos Corporation Does
Glaukos Corporation develops innovative therapies for eye diseases, especially glaucoma. Its products include micro-bypass stents and other technologies aimed at lowering intraocular pressure. The company's focus on enhancing treatment options places it in a crucial space within the healthcare industry, especially as demand for effective glaucoma therapies rises.
What's Ahead for Glaukos Corporation
Investors will be keenly watching Glaukos as it approaches its next earnings date on October 28, 2026. The backward-looking nature of analyst ratings means that while Citigroup's current target reflects optimism, market conditions and company performance will ultimately shape future trading. With a strong analyst consensus and positive revenue growth, Glaukos could be positioned for a rebound as it navigates the challenges ahead.
Related Filing Alerts
Source: Citigroup's rating change on $GKOS (Jun 11, 2026). Written by software, not financial advice. How we make alerts